BROOMFIELD, Colo., Aug. 14 ARCA biopharma, Inc., abiopharmaceutical company developing genetically-targeted therapies for heartfailure and other cardiovascular diseases, announced today that it hasappointed William R. Hiatt, MD, as Director of Clinical and RegulatoryStrategy. In this newly created position, Dr. Hiatt will be responsible fordeveloping strategic regulatory and clinical initiatives designed to supportthe company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride),a pharmacologically unique beta-blocker and mild vasodilator in late-stagedevelopment for heart failure, as well as other compounds in ARCA's pipeline.
"Dr. Hiatt is a recognized expert who knows cardiovascular medicine fromvirtually every angle: as researcher, physician, educator, clinician andformer advisor to the U.S. Food and Drug Administration," said Richard B.Brewer, president and chief executive officer of ARCA biopharma. "He bringsvaluable experience and insight to ARCA as we prepare to introduce our firstproduct and begin to educate the medical community about the benefits ofgenetically targeted treatment of heart failure."
"I look forward to working with the talented men and women at ARCA tobring important new solutions to heart failure patients," said Dr. WilliamHiatt. "By inaugurating the personalized medicine trail in the heart failurearena, ARCA is changing the way we offer treatment to patients with thisserious chronic condition."
Dr. Hiatt is Professor of Medicine, Professor of Cardiovascular Researchand Chief of the Section of Vascular Medicine at the University of ColoradoDenver's Anschutz Medical Campus. Throughout his career, Dr. Hiatt's researchhas focused on developing new therapies for patients with peripheral arterialdisease and understanding its pathophysiology in terms of the effects ofmuscle ischemia on muscle metabolism and function. Dr. Hiatt also isPresident of the Colorado Prevention Center, a non-profit medical research anddisease prevention center affiliated with the university that promotes diseaseprevention through clinical trials and outreach programs. In addition, Dr.Hiatt served on the FDA Cardiovascular and Renal Advisory Committee from 2003until 2008, and was Chairman of the Cardiovascular and Renal Drugs Committeefrom January 2006 to June 2008.
Dr. Hiatt received his medical degree cum laude from the University ofColorado School of Medicine; he completed his residence at Boston UniversityHospital and the University of Colorado Health Sciences Center in 1979. Hecompleted a fellowship in internal medicine and vascular medicine at theUniversity of Colorado in 1981. He is Past President of the Society forVascular Medicine and Biology and serves as an advisor to the Board of theInternational Union of Angiology.
About ARCA biopharma
ARCA biopharma, Inc. is a privately held company focused on developing andcommercializing genetically targeted therapies for heart failure and othercardiovascular diseases. The Company's lead product, Gencaro(TM) (bucindololhydrochloride), is a pharmacologically unique beta-blocker and mildvasodilator being developed for heart failure and other indications. ARCA hasidentified common genetic variations that predict individual patient responseto Gencaro. The company plans to file a New Drug Application with the U.S.Food and Drug Administration during the summer of 2008 for approval of Gencarofor the treatment of heart failure. The companion genetic test for Gencaro isin development by ARCA's partner, Laboratory Corporation of America. Ifapproved, Gencaro could become the first genetically personalizedcardiovascular therapy. For more information please visithttp://www.arcabiopharma.com.
SOURCE ARCA biopharma, Inc.